Scientists prove for the first time that cardiac pacemaker cells are expected to replace electronic pacemakers
For the first time, scientists have developed functional pacemaker cells from human stem cells, paving the way for alternative biological pacemaker therapy. According to a report published in the December 12th issue of "Natural Biological Science", sinoatrial cardiomyocytes are human pluripotent stem cells that act as biological pacing, and pluripotent stem cells will form in 21 days and develop into pacing. Cells, and use electrical impulses to regularly beat the heart. These human pacemaker cells were tested in the heart of mice to prove that their function is the same as that of the organism, triggering cardiac contraction by stimulating electrical impulses. Pluripotent stem cells may be divided into more than 200 different cell types that make up various tissues and organs of the body. Sinus node pacemaker cells are the main pacemakers of the heart, controlling the beating of the heart throughout life. If there is a problem with the pacemaker, it will cause a heart rhythm disorder. The usual treatment plan is to implant an electronic pacing device. Understanding how to form pacing cells contributes to cellular disorders and provides a source of cells for the development of biological pacemakers. The replacement of electronic pacemakers with biological pacemakers is promising because it avoids some of the problems caused by electronic pacemakers, such as hormonal responses, which cannot accommodate changes in the size of the heart in pediatric patients. Scientists use developmental biology to grow pacemaker cells. "We use the human body as a petri dish and cultivate the pacemaker cells in a natural way." Research said.
Kidney diseases are very harmful to the human body. Kidney diseases are also very painful for the human body. Kidney diseases seriously endanger human health. The main clinical manifestations of renal disease include hypertension, hematuria, proteinuria and renal insufficiency.The causes of kidney disease are complex. As little is known about most "primary" glomerular diseases, the management of the global disease is clinical and there is no clear etiological treatment. As a result, clinical trials aimed at treating the global disease are very limited.The raw materials we provide in kidney drugs mainly include:Trelagliptin Succinate,linagliptin,Trelagliptin succinate,Entecavir,Bimatoprost,Choline Bitartrate,Barley extract,Barley malt extract,Trimethoprim,Monensin,Rhizoma Coptidis,Rhizoma Coptidis extract,Glycyrrhizic acid dipotassium,Glycyrrhizic acid,Pantoprazole Sodium,Lansoprazole.
Natural Kidney Medicine,Vitamin C Minoxidil,Dinoprostone Api Powder,Yohimbine Hcl Powder Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikang.com